2 days ago
NewLimit Series C: Armstrong-Backed Longevity Startup Raises $435M
FintechTechnologybiotech fundingBrian Armstrongcrypto foundersepigenetic reprogrammingFounders Fundhuman trialslongevity biotechNewLimitSeries C
TLDR: NewLimit Series C raised $435M led by Founders Fund for longevity biotech expansion and clinical readiness. Startup targets epigenetic reprogramming therapies aimed at restoring youthful function in aged human cells. First-in-human trials for lead liver cell program are planned for next year after recent breakthrough results. Funding brings major VC backing as NewLimit scales [...]
The post NewLimit Series C: Armstrong-Backed Longevity Startup Raises $435M appeared first on Blockonomi.
Source: Blockonomi →Related News
- 5 hours ago
Zcash Bug Crisis Shows Privacy Cuts Both Ways, Experts Say
- 1 day ago
Coinbase Launches Pre-IPO Perpetual Futures, Beginning with SpaceX
- 1 day ago
Spacecoin Signs $100M Vietnam Deal to Deploy Decentralized Satellite Network
- 2 days ago
Outpoll Launches Global Prediction Market Platform Built Around Professional Tra...
- 2 days ago
Walrus Memory Enables AI Agents to ‘Actually Learn About Us’: Mysten Labs Co-Fou...